Biorestorative Therapies (BRTX)
(Delayed Data from NSDQ)
$1.34 USD
-0.01 (-0.74%)
Updated Apr 23, 2024 04:00 PM ET
After-Market: $1.34 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth B Momentum D VGM
Price, Consensus and EPS Surprise
BRTX 1.34 -0.01(-0.74%)
Will BRTX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for BRTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BRTX
QIAGEN (QGEN) Extends the AI-Powered QCI Interpret Software
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue Estimates
BRTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Mirati (MRTX) Reports Q2 Loss, Misses Revenue Estimates
Other News for BRTX
Optimistic Outlook for BioRestorative Therapies Backed by Clinical and Strategic Advances
BioRestorative's BRTX-100 trial to use sham injection control, says Roth MKM
BioRestorative gains as FDA clears amendment to study on cell therapy candidate
BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment
12 Health Care Stocks Moving In Tuesday's Pre-Market Session